A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred Diethylstilbestrol

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 620-628

  Shamash, J ^a   Powles, T ^a   Sarker, S J ^b   Protheroe, A ^c   Mithal, N ^d   Mills, R ^e   Beard, R ^f   Wilson, P ^a   Tranter, N ^b   O'Brien, N ^g   McFaul, S ^a   Oliver, T ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f WORTHING HOSPITAL   (United Kingdom)

^g QUEEN S HOSPITAL   (United Kingdom)

Author keywords

CRPC; Dexamethasone; Diethylstilbestrol; treatment sequencing

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; DEXAMETHASONE; DIETHYLSTILBESTROL; GONADORELIN DERIVATIVE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; RANITIDINE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CASTRATION; DEEP VEIN THROMBOSIS; DRUG INDUCED HEADACHE; FLUID RETENTION; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MASTALGIA; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MYOPATHY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; SIDE EFFECT; SKIN TOXICITY; THERAPY DELAY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; DEXAMETHASONE; DIETHYLSTILBESTROL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG TOXICITY; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79951678465     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.7     Document Type: Article

References (22)

1. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23): 3742-3748
2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28): 4563-4571
3. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17(11): 3461-3467 (Pubitemid 29517916)
4. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT (2000) Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 85(9): 1069-1073 (Pubitemid 30348801)
5. Fossa SD, Slee TPH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, Prijck L, de Collette L (2001) Flutamide vs Prednisone in patients with prostate cancer symptomatically progressing after andro-gen ablative therapy-a phase III study of the European Organization for Reseach and Treatment of Cancer Genitourinary Group. J Clin Oncol 19: 62-71 (Pubitemid 32063480)
6. Grigoryev DN, Long BJ, Njar VC, Brodie AH (2000) Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 75(1): 1-10 (Pubitemid 32155418)
7. Hellerstedt BA, Pienta KJ (2002) The current state ofhormonal therapy for prostate cancer. CA Cancer J Clin 52(3): 154-179 (Pubitemid 34546107)
8. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24(24): 3984-3990 (Pubitemid 46630748)
9. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17(8): 2506-2513 (Pubitemid 29368252)
10. Machin D, Campbell M, Tan SB, Tan SH (2008) Sample Size Tables for Clinical Studies, 3rd edn, Blackwell: Oxford, UK
11. Mottet N, Peneau M, Mazeron J, Molinie VPR (2010) Impact of radiotherapy (RT) combined with androgen deprivation (ADT) vs ADT alone for local control in clinically locally advanced prostate cancer. Proc ASCO 4505: 343S
12. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T, Okuyama A (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89(12): 2570-2576 (Pubitemid 32011601)
13. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520 (Pubitemid 39315318)
14. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7): 1148-1159
15. Shamash J, Davies A, Ansell W, McFaul S, Wilson P, Oliver T, Powles T (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98(1): 22-24
16. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi A, McLeod DG, Srivastava S (2006) Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25(28): 3905-3913 (Pubitemid 43990745)
17. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512 (Pubitemid 39315317)
18. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.(see comment). J Clin Oncol 14(6): 1756-1764 (Pubitemid 26185452)
19. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials, D Moher, KF Schulz, DG Altman, BMC Med Res Methodol 2001, 1: 2
20. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101(4): 440-443 (Pubitemid 351160930)
21. Warde PR, Mason MD, Sydes MR, Gospodarowicz MK, Swanson GP, Kirkbride P, Kostashuk E, Hetherington J, Ding K, Parulekar W (2010) Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). Proc ASCO CRA 4504: 959S
22. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89(3): 589-596 (Pubitemid 30640105)